AstraZeneca To Cut 3,000 Jobs As It Seeks To Rationalize Production Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO David Brennan tells investors the decision is another step in the company’s program to increase efficiencies.
You may also be interested in...
AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate
New company Albireo will be financed initially with $27 million from three growth capital firms.
AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate
New company Albireo will be financed initially with $27 million from three growth capital firms.
AstraZeneca Hits Anti-Infective Target With Arrow Acquisition
Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.